Clinical Trial Detail

NCT ID NCT01445509
Title Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

Bevacizumab

Dasatinib

Age Groups: adult senior

No variant requirements are available.